11β-HSD1 Plays a Critical Role in Trabecular Bone Loss Associated with Systemic Glucocorticoid Therapy

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2019 Aug 18

PMID 31420008

Citations 19

Authors

C G Fenton

C L Doig

S Fareed

A Naylor

A P Morrell

O Addison

C Wehmeyer

C D Buckley

M S Cooper

G G Lavery

K Raza

R S Hardy

Affiliations

Soon will be listed here.

Abstract

Background: Despite their efficacy in the treatment of chronic inflammation, the prolonged application of therapeutic glucocorticoids (GCs) is limited by significant systemic side effects including glucocorticoid-induced osteoporosis (GIOP). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bi-directional enzyme that primarily activates GCs in vivo, regulating tissue-specific exposure to active GC. We aimed to determine the contribution of 11β-HSD1 to GIOP.

Methods: Wild type (WT) and 11β-HSD1 knockout (KO) mice were treated with corticosterone (100 μg/ml, 0.66% ethanol) or vehicle (0.66% ethanol) in drinking water over 4 weeks (six animals per group). Bone parameters were assessed by micro-CT, sub-micron absorption tomography and serum markers of bone metabolism. Osteoblast and osteoclast gene expression was assessed by quantitative RT-PCR.

Results: Wild type mice receiving corticosterone developed marked trabecular bone loss with reduced bone volume to tissue volume (BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N). Histomorphometric analysis revealed a dramatic reduction in osteoblast numbers. This was matched by a significant reduction in the serum marker of osteoblast bone formation P1NP and gene expression of the osteoblast markers Alp and Bglap. In contrast, 11β-HSD1 KO mice receiving corticosterone demonstrated almost complete protection from trabecular bone loss, with partial protection from the decrease in osteoblast numbers and markers of bone formation relative to WT counterparts receiving corticosterone.

Conclusions: This study demonstrates that 11β-HSD1 plays a critical role in GIOP, mediating GC suppression of anabolic bone formation and reduced bone volume secondary to a decrease in osteoblast numbers. This raises the intriguing possibility that therapeutic inhibitors of 11β-HSD1 may be effective in preventing GIOP in patients receiving therapeutic steroids.

Citing Articles

Tau(t)ing glucocorticoid binding.

Vettorazzi S, Tuckermann J Cell Res. 2025; 35(1):1-2.

PMID: 39743631 PMC: 11701119. DOI: 10.1038/s41422-024-01041-z.

Meta-analysis of the efficacy and safety of vamorolone in Duchenne muscular dystrophy.

Ibrahim M, Abdelwahab O, Elawfi B, Ali F, Amro S, Mohammed S Neurol Sci. 2024; .

PMID: 39715964 DOI: 10.1007/s10072-024-07939-1.

Structured Polymers Enable the Sustained Delivery of Glucocorticoids within the Intra-Articular Space.

Crastin A, Martin C, Suresh S, Davies S, Kearns D, Parlak A Adv Healthc Mater. 2024; 14(4):e2403000.

PMID: 39713898 PMC: 11804841. DOI: 10.1002/adhm.202403000.

Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity.

Zhong C, Li N, Wang S, Li D, Yang Z, Du L Nat Commun. 2024; 15(1):8588.

PMID: 39362888 PMC: 11449908. DOI: 10.1038/s41467-024-52965-4.

Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.

Ahmet A, Tobin R, Dang U, Rooman R, Guglieri M, Clemens P J Clin Endocrinol Metab. 2024; 110(2):334-344.

PMID: 39097643 PMC: 11747748. DOI: 10.1210/clinem/dgae521.

References

Yao W, Cheng Z, Busse C, Pham A, Nakamura M, Lane N . Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58(6):1674-86. PMC: 3892702. DOI: 10.1002/art.23454. View

Arner P, Gunnarsson R, Blomdahl S, Groth C . Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983; 6(1):23-5. DOI: 10.2337/diacare.6.1.23. View

Feldstein A, Elmer P, Nichols G, Herson M . Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int. 2005; 16(12):2168-74. DOI: 10.1007/s00198-005-2016-z. View

Sury M, Russell G, Heaf D . Hydrocortisone myopathy. Lancet. 1988; 2(8609):515. DOI: 10.1016/s0140-6736(88)90169-9. View

Woitge H, Harrison J, Ivkosic A, Krozowski Z, Kream B . Cloning and in vitro characterization of alpha 1(I)-collagen 11 beta-hydroxysteroid dehydrogenase type 2 transgenes as models for osteoblast-selective inactivation of natural glucocorticoids. Endocrinology. 2001; 142(3):1341-8. DOI: 10.1210/endo.142.3.8044. View

Lavery G, Walker E, Draper N, Jeyasuria P, Marcos J, Shackleton C . Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem. 2005; 281(10):6546-51. DOI: 10.1074/jbc.M512635200. View

Bouxsein M, Lewis B, Charette S, Weinstein P, Marcus R . Muscle strength as a predictor of bone mineral density in young women. J Bone Miner Res. 1990; 5(6):589-95. DOI: 10.1002/jbmr.5650050608. View

Bland R, Worker C, Noble B, Eyre L, Bujalska I, Sheppard M . Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J Endocrinol. 1999; 161(3):455-64. DOI: 10.1677/joe.0.1610455. View

Strehl C, Bijlsma J, de Wit M, Boers M, Caeyers N, Cutolo M . Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016; 75(6):952-7. DOI: 10.1136/annrheumdis-2015-208916. View

10.

Weinstein R, Hogan E, Borrelli M, Liachenko S, OBrien C, Manolagas S . The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice. Endocrinology. 2017; 158(11):3817-3831. PMC: 5695837. DOI: 10.1210/en.2017-00662. View

11.

Sher L, Woitge H, Adams D, Gronowicz G, Krozowski Z, Harrison J . Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology. 2003; 145(2):922-9. DOI: 10.1210/en.2003-0655. View

12.

Kaur K, Hardy R, Ahasan M, Eijken M, van Leeuwen J, Filer A . Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis. 2009; 69(6):1185-90. PMC: 2927616. DOI: 10.1136/ard.2009.107466. View

13.

Morgan S, McCabe E, Gathercole L, Hassan-Smith Z, Larner D, Bujalska I . 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A. 2014; 111(24):E2482-91. PMC: 4066483. DOI: 10.1073/pnas.1323681111. View

14.

Johnson T, Whitaker M, Keevil B, Ross R . Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. J Bioequivalence Bioavailab. 2018; 10(1):001-3. PMC: 5963674. DOI: 10.4172/jbb.1000365. View

15.

Cooper M, Walker E, Bland R, Fraser W, Hewison M, Stewart P . Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone. 2000; 27(3):375-81. DOI: 10.1016/s8756-3282(00)00344-6. View

16.

Rauch A, Seitz S, Baschant U, Schilling A, Illing A, Stride B . Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010; 11(6):517-31. DOI: 10.1016/j.cmet.2010.05.005. View

17.

Plotkin L, Manolagas S, Bellido T . Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J Biol Chem. 2007; 282(33):24120-30. DOI: 10.1074/jbc.M611435200. View

18.

Dourakis S, Sevastianos V, Kaliopi P . Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002; 97(4):1074-5. DOI: 10.1111/j.1572-0241.2002.05644.x. View

19.

Frerichs V, Tornatore K . Determination of the glucocorticoids prednisone, prednisolone, dexamethasone, and cortisol in human serum using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 802(2):329-38. DOI: 10.1016/j.jchromb.2003.12.015. View

20.

Calogero A, Burrello N, Bosboom A, Garofalo M, WEBER R, DAgata R . Glucocorticoids inhibit gonadotropin-releasing hormone by acting directly at the hypothalamic level. J Endocrinol Invest. 1999; 22(9):666-70. DOI: 10.1007/BF03343627. View